Novartis Ag Adr Stock Beta
| NVS Stock | USD 109.06 0.05 0.05% |
Novartis AG ADR fundamentals help investors to digest information that contributes to Novartis' financial success or failures. It also enables traders to predict the movement of Novartis Stock. The fundamental analysis module provides a way to measure Novartis' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novartis stock.
Novartis | Beta |
Novartis AG ADR Company Beta Analysis
Novartis' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Novartis Beta | 0.49 |
Most of Novartis' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novartis AG ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Novartis Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for Novartis is extremely important. It helps to project a fair market value of Novartis Stock properly, considering its historical fundamentals such as Beta. Since Novartis' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Novartis' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Novartis' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Novartis AG ADR has a Beta of 0.49. This is 43.02% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Novartis Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novartis' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Novartis could also be used in its relative valuation, which is a method of valuing Novartis by comparing valuation metrics of similar companies.Novartis is currently under evaluation in beta category among its peers.
Novartis ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Novartis' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Novartis' managers, analysts, and investors.Environmental | Governance | Social |
Novartis Institutional Holders
Institutional Holdings refers to the ownership stake in Novartis that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Novartis' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Novartis' value.| Shares | Goldman Sachs Group Inc | 2024-12-31 | 2.3 M | Cullen Capital Management, Llc | 2024-12-31 | 2.2 M | Northern Trust Corp | 2024-12-31 | 2.1 M | Fisher Asset Management, Llc | 2024-12-31 | 2 M | Blackrock Inc | 2024-12-31 | 2 M | Envestnet Asset Management Inc | 2024-12-31 | 1.9 M | Wells Fargo & Co | 2024-12-31 | 1.9 M | Ubs Group Ag | 2024-12-31 | 1.7 M | State Street Corp | 2024-12-31 | 1.6 M | Dodge & Cox | 2024-12-31 | 12.2 M | Primecap Management Company | 2024-12-31 | 11 M |
As returns on the market increase, Novartis' returns are expected to increase less than the market. However, during the bear market, the loss of holding Novartis is expected to be smaller as well.
Novartis Fundamentals
| Return On Equity | 0.26 | ||||
| Return On Asset | 0.1 | ||||
| Profit Margin | 0.23 % | ||||
| Operating Margin | 0.30 % | ||||
| Current Valuation | 233.47 B | ||||
| Shares Outstanding | 1.98 B | ||||
| Shares Owned By Institutions | 6.76 % | ||||
| Number Of Shares Shorted | 5.04 M | ||||
| Price To Earning | 9.22 X | ||||
| Price To Book | 4.89 X | ||||
| Price To Sales | 4.17 X | ||||
| Revenue | 51.72 B | ||||
| Gross Profit | 38.91 B | ||||
| EBITDA | 20.71 B | ||||
| Net Income | 11.94 B | ||||
| Cash And Equivalents | 4.64 B | ||||
| Cash Per Share | 8.84 X | ||||
| Total Debt | 31.26 B | ||||
| Debt To Equity | 0.47 % | ||||
| Current Ratio | 1.31 X | ||||
| Book Value Per Share | 22.30 X | ||||
| Cash Flow From Operations | 17.62 B | ||||
| Short Ratio | 2.17 X | ||||
| Earnings Per Share | 5.87 X | ||||
| Price To Earnings To Growth | 3.26 X | ||||
| Target Price | 108.96 | ||||
| Number Of Employees | 75.88 K | ||||
| Beta | 0.49 | ||||
| Market Capitalization | 215.56 B | ||||
| Total Asset | 102.25 B | ||||
| Retained Earnings | 49.65 B | ||||
| Working Capital | 1.01 B | ||||
| Current Asset | 22.84 B | ||||
| Current Liabilities | 23.71 B | ||||
| Annual Yield | 0.04 % | ||||
| Five Year Return | 3.53 % | ||||
| Net Asset | 102.25 B | ||||
| Last Dividend Paid | 3.86 |
About Novartis Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novartis AG ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novartis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novartis AG ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Novartis Stock Analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.